Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

August 2022 in “ Microorganisms ”

Frauke Assmus, Jean‐Sélim Driouich, Rana Abdelnabi, Laura Vangeel, Franck Touret, Ayorinde Adehin, Palang Chotsiri, Maxime Cochin, Caroline S. Foo, Dirk Jochmans, Seungtaek Kim, Léa Lucıanı, Grégory Moureau, Soonju Park, Paul-Rémi Petit, David Shum, Thanaporn Wattanakul, Birgit Weynand, Laurent Fraisse, Jean‐Robert Ioset, Charles E. Mowbray, Andrew Owen, Richard M. Hoglund, Joel Tärning, Xavier de Lamballerie, Antoine Nougaırède, Johan Neyts, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain

Studysummary This study reports that drug repurposing for COVID-19 has had mixed results, with success for some drugs but a lack of clinical efficacy for others, highlighting the need for improved preclinical profiling and a standardized drug development platform for future antiviral treatments.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

research Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

42 citations , July 2021 in “Frontiers in Medicine”

In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.

research Cepharanthine: A Review of the Antiviral Potential of a Japanese-Approved Alopecia Drug in COVID-19

70 citations , July 2020 in “Pharmacological Reports”

This review discusses the antiviral potential of cepharanthine against SARS-CoV-2, noting its effectiveness in preclinical models but presenting no new clinical results.

Discovery of Clinically Approved Drugs Capable of Inhibiting SARS-CoV-2 In Vitro Infection Using a Phenotypic Screening Strategy and Network-Analysis to Predict Their Potential to Treat COVID-19

research Discovery of Clinically Approved Drugs Capable of Inhibiting SARS-CoV-2 In Vitro Infection Using a Phenotypic Screening Strategy and Network-Analysis to Predict Their Potential to Treat COVID-19

13 citations , July 2020 in “bioRxiv (Cold Spring Harbor Laboratory)”

This study identified four drugs, including brequinar and abiraterone acetate, that inhibited SARS-CoV-2 infection in vitro, providing potential candidates for repurposing to treat COVID-19.